Enzolytics Inc (ENZC)

[MC$Trader]

Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number
ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into
partnership agreements with newcomers, or with companies in different stages of development in the research pipeline,
combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action.
Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching
over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues,
among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents
impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
I know it's Super Bowl but I would say we have a Home Run!!!